Optum Tightens Commercial ABA Claim Rules for 2026

What Changes on Commercial Claims

Starting with the 2026 plan year, Optum will reject any commercial behavioral health claim that does not carry a National Provider Identifier (NPI) and taxonomy code for both the billing provider and the person who actually delivered the service. For applied behavior analysis practices, that means a claim for a session a registered behavior technician (RBT) ran under a clinic’s group NPI will bounce unless the rendering provider’s NPI and taxonomy ride along with it.

Optum Behavioral Health laid out the change in a September 2025 notice to providers. Every claim for a member on a commercial, employer-sponsored plan must list the NPI and taxonomy for the billing provider and the rendering provider, and the codes will be checked automatically against the federal National Plan and Provider Enumeration System (NPPES). Claims missing the data, or carrying it in the wrong field, will be rejected or denied, the company said.

Optum provided a runway. It began flagging non-compliant claims with informational edits in October 2025, a soft launch that marks the missing fields without holding up payment. The firm effective date, Optum said, would be announced in the first quarter of 2026 with an advance-notification period before enforcement begins.

The requirement reaches every commercial behavioral health claim, not ABA alone. ABA practices sit squarely in its path, because they routinely bill a group NPI for services that individual analysts and technicians render. On electronic 837P claims, the rendering NPI and taxonomy belong in the 2310 and 2420 loops; on paper, in boxes 24I and 24J. Optum requires the rendering detail whenever it differs from the billing provider, which in a group practice is nearly always. For behavior analysts, the taxonomy code is 103K00000X.

The Diagnostic Records That Gate Coverage

A clean claim is only half the job. Whether Optum authorizes ABA at all turns on the diagnostic file behind the request. Under Optum’s clinical criteria, one accepted route to preauthorization is a comprehensive diagnostic evaluation completed within the past three years, paired with a referral for ABA made within the past six months.

Optum’s published criteria list what a thorough evaluation should contain: a caregiver interview, direct observation of the core features of autism, a developmental history, a record of current functioning, and a clear statement of the autism spectrum disorder diagnosis. Standardized diagnostic instruments, among them the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition) and the CARS-2 (Childhood Autism Rating Scale, Second Edition), are listed as recommended rather than strictly required.

In practice, providers say the distance between “recommended” and “required” is closing. Intake teams that work UnitedHealthcare cases report that for 2026, a diagnosis draws denials when it is older than three years, lacks a standardized instrument such as the ADOS-2 or CARS-2, or does not carry an explicit recommendation for ABA therapy, according to guidance published by ABA Solutions, a Florida provider, and the billing resource Praxis Notes. The safest file now reads like a checklist: a recent evaluation, a named standardized measure, and the words “ABA therapy” in the recommendation.

Why Optum Is Pressing Now

The commercial tightening lands after a year of scrutiny over how Optum manages ABA. In December 2024, ProPublica reported, citing internal company documents, that Optum was using what it called “rigorous utilization management” to curb spending on ABA in its Medicaid plans: halting new provider additions in some markets, cutting contracts with providers it judged “outliers,” and building an “approach to authorizing less units than requested.”

The same documents, ProPublica reported, also acknowledged ABA’s clinical value even as they mapped ways to limit it. Optum said the article “grossly misrepresents” its work and that its programs comply with federal and state law and follow widely accepted industry standards.

“ABA is the evidence-based gold standard treatment for those with medically necessary needs.” – Optum internal report, as reported by ProPublica (2024)

That investigation centered on Medicaid, not the commercial plans the 2026 claim rule governs. The two move in the same direction: more documentation, more verification, and more points at which a claim or an authorization can fail. Karen Fessel, an autism-insurance access advocate quoted by ProPublica, called the Medicaid tactics “unconscionable and immoral.” Optum has also trimmed behavioral health reimbursement rates over the same period.

How to Stay Out of the Denial Pile

For practices, the work splits into two tracks: the billing file and the intake file. Neither is complicated, but both have to be right before the first 2026 claim goes out.

On billing, start in NPPES. Confirm that every analyst and technician has an active NPI with the correct taxonomy and that the group’s record is accurate, since Optum validates against that database. Then set the practice-management system or clearinghouse to drop the rendering NPI and taxonomy into the 2310 and 2420 loops automatically, and run test claims against Optum’s informational edits, which have flagged missing fields since October 2025 without stopping payment. That window is the free trial: a flagged edit today is a denied claim in 2026.

On intake, treat the diagnostic report as a gating document. Before submitting an authorization request, confirm the evaluation is under three years old, names a standardized instrument, and recommends ABA therapy in plain words, and that a referral falls inside the six-month window. Where a diagnosis is stale or thin, a fresh evaluation is cleaner than an appeal after the denial.

Optum said the firm effective date would arrive in 2026 with an advance-notification period before enforcement. The informational edits have run since October 2025, which makes the practical deadline now, not the day the cutover finally lands.

AT A GLANCE

SOURCES & REFERENCES